يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"O'Neill, Brianne"', وقت الاستعلام: 0.30s تنقيح النتائج
  1. 1
    Conference
    748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

    المؤلفون: Sanborn, Rachel E, Furqan, Muhammad, Laux, Doug, Sharma, Manish, Olson, Daniel, Berz, David, Hauke, Ralph J, Massarelli, Erminia, Steuer, Conor, Davis, Elizabeth, Iams, Wade T, Thompson, Jonathan, Hamm, John, Andrianov, Vasily, O’Neill, Brianne, Durana, Yaiza Diaz De, Tolcher, Anthony W

    المصدر: Regular and Young Investigator Award Abstracts ; page A844-A844

    الاتاحة: http://dx.doi.org/10.1136/jitc-2023-sitc2023.0748
    https://syndication.highwire.org/content/doi/10.1136/jitc-2023-SITC2023.0748

    View record in BASE

    أضف إلى المفضلة
  2. 2
    Conference
    742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

    المؤلفون: Park, Jong Chul, Berz, David, Sharma, Manish, Massarelli, Erminia, Hauke, Ralph J, Tsai, Frank Yung-Chin, Hong, David, Akhave, Neal, Call, Justin A, Carlisle, Jennifer, Sanborn, Rachel E, Haas, Naomi B, Hamm, John, Ross Camidge, D, Spira, Alexander I, Andrianov, Vasily, O’Neill, Brianne, Kinkead, Heather, Tolcher, Anthony W

    المصدر: Regular and Young Investigator Award Abstracts ; page A836-A837

    الاتاحة: http://dx.doi.org/10.1136/jitc-2023-sitc2023.0742
    https://syndication.highwire.org/content/doi/10.1136/jitc-2023-SITC2023.0742

    View record in BASE

    أضف إلى المفضلة
  3. 3
    Academic Journal
    Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.

    المؤلفون: Berz, David, Alese, Olatunji B., Hong, David S., Lakhani, Nehal J., Elez, Elena, Sharma, Manish R, O'Neill, Brianne, Li, Yang, Piccione, Emily, Kalabus, James, Garcia, Josep, Hartner, Lee P., Lieu, Christopher Hanyoung

    المصدر: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p129-129, 307p


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء